117 results on '"Lasser, Luc"'
Search Results
2. THU-092 Enrolling patients in ACLF trials-the need to increase ACLF awareness (DHELIVER trial)
- Author
-
Thabut, Dominique, primary, Rudler, Marika, additional, Janczewska, Ewa, additional, van der Merwe, Schalk, additional, Nevens, Frederik, additional, Lannes, Adrien, additional, Lasser, Luc, additional, Reiberger, Thomas, additional, Brjalin, Vadim, additional, Pavlova, Desislava, additional, Selcanova, Svetlana Adamcova, additional, Katzarov, Krum, additional, Draganov, Ventseslav, additional, Collienne, Christine, additional, Bureau, Christophe, additional, Saviano, Antonio, additional, Toniutto, Pierluigi, additional, González, Javier Martínez, additional, Sánchez, Jordi, additional, Borissova, Julia, additional, Genov, Jordan, additional, Nikolov, Ivaylo, additional, Gustot, Thierry, additional, Pageaux, Georges-Philippe, additional, Antonini, Teresa, additional, Borentain, Patrick, additional, Leroy, Vincent, additional, Perricone, Giovanni, additional, Grønbæk, Henning, additional, Maasoumy, Benjamin, additional, Bruns, Tony, additional, Pukitis, Aldis, additional, Kupčinskas, Juozas, additional, Stardelova, Kalina Grivcheva, additional, Dimitrova, Magdalena Genadieva, additional, Todorovska, Beti, additional, Eggermont, Fabienne, additional, Vainilovich, Yelena, additional, Lin, Frederic, additional, Gordillo, Noelia, additional, Goddemaer, Griet, additional, Najimi, Mustapha, additional, and Sokal, Etienne, additional more...
- Published
- 2024
- Full Text
- View/download PDF
Catalog
3. A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation
- Author
-
Nevens, Frederik, Gustot, Thierry, Laterre, Pierre-François, Lasser, Luc L., Haralampiev, Lyudmil E., Vargas, Victor, Lyubomirova, Desislava, Albillos, Agustin, Najimi, Mustapha, Michel, Sébastien, Stoykov, Ivaylo, Gordillo, Noelia, Vainilovich, Yelena, Barthel, Virginie, Clerget-Chossat, Nathalie, and Sokal, Etienne M. more...
- Published
- 2021
- Full Text
- View/download PDF
4. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial
- Author
-
Moussata, Driffa, Grangé, Jean-Didier, Ratziu, Vlad, Khemissa-Akouz, Faiza, Regnault, Hélène, Dauvois, Barbara, Zarski, Jean-Pierre, Ollivier-Hourmand, Isabelle, Manfredi, Sylvain, Debette-Gratien, Marilyne, Gangloff, Alice, Fontanges, Thierry, Baron, Aurore, Bouattour, Mohamed, Vincent, Julie, Sieghart, Wolfgang, Maieron, Andreas, Peeters, Marc, Delwaide, Jean, Lasser, Luc, Berg, Thomas, Schultheiß, Michael, Zipprich, Alexander, Trojan, Joerg, Ehmer, Ursula, Luppi, Gabriele, Luca, Giovanni, Tamberi, Stefano, Amoroso, Domenico, Alabiso, Oscar, Buonadonna, Angela, Toniutto, Pierluigi, Tamburini, Emiliano, Cubillo, Antonio, Muñoz, Andrés, Guillén, Carmen, Sánchez, Gloria, Manzano, Hermini, Navarro, Victor, Ales, Inmaculada, Massuti, Bartomeu, Dank, Magdolna, Bodoky, György, Kahan, Zsuzsanna, Horváth, Zsolt, Gabrail, Nashat, Ozer, Howard, Galanopoulos, Christos, Hauke, Ralph, Raj, Moses, Harputluoglu, Hakan, Sevinc, Alper, Goker, Erdem, Coker, Ahmet, Yalcin, Suayib, Ali, Muhammet, Ata, Ozlem, Tugba, Ilkay, El Kassas, Mohammed, Abdel, Amr, Wakid, Imam, Shamaa, Sameh, El Lahlouby, Nasr, Kohail, Hanaa, Makarem, Jawad, Chehade, Issam, Farhat, Fadi, López, Carlos, Marín, Miguel, Merle, Philippe, Blanc, Jean-Frederic, Phelip, Jean-Marc, Pelletier, Gilles, Bronowicki, Jean-Pierre, Touchefeu, Yann, Pageaux, Georges, Gerolami, René, Habersetzer, François, Nguyen-Khac, Eric, Casadei-Gardini, Andrea, Borbath, Ivan, Tran, Albert, Wege, Henning, Saad, Amr Shafik, Colombo, Massimo, Abergel, Armand, Richou, Carine, Waked, Imam, Yee, Nelson S, Molé, Audrey, Attali, Pierre, Le Boulicaut, Julie, and Vasseur, Bérangère more...
- Published
- 2019
- Full Text
- View/download PDF
5. ACLF course profiles over screening period in the phase IIb DHELIVER study
- Author
-
Nevens, Frederik, primary, Thabut, Dominique, additional, Rudler, Marika, additional, Adrien, Lannes, additional, Lasser, Luc, additional, Brjalin, Vadim, additional, Pageaux, Georges-Philippe, additional, Janczewska, Ewa, additional, Toniutto, Pierluigi, additional, Martinez, Javier, additional, Reiberger, Thomas, additional, Sánchez-Delgado, Jordi, additional, Vargas, Victor, additional, Gustot, Thierry, additional, Maasoumy, Benjamin, additional, Grønbæk, Henning, additional, Bruns, Tony, additional, Bureau, Christophe, additional, Stardelova, Kalina Grivcheva, additional, Pavlova, Desislava, additional, Nikolov, Ivaylo, additional, Katzarov, Krum, additional, Draganov, Ventseslav, additional, Monterde, Vanesa Bernal, additional, Gordillo, Noelia, additional, Vainilovich, Yelena, additional, Najimi, Mustapha, additional, Barthel, Virginie, additional, Lin, Frederic, additional, and Sokal, Etienne, additional more...
- Published
- 2023
- Full Text
- View/download PDF
6. Alcohol intake increases the risk of HCC in hepatitis C virus-related compensated cirrhosis: A prospective study
- Author
-
Vandenbulcke, Hélène, Moreno, Christophe, Colle, Isabelle, Knebel, Jean-François, Francque, Sven, Sersté, Thomas, George, Christophe, de Galocsy, Chantal, Laleman, Wim, Delwaide, Jean, Orlent, Hans, Lasser, Luc, Trépo, Eric, Van Vlierberghe, Hans, Michielsen, Peter, van Gossum, Marc, de Vos, Marie, Marot, Astrid, Doerig, Christopher, Henrion, Jean, and Deltenre, Pierre more...
- Published
- 2016
- Full Text
- View/download PDF
7. Intensive Enteral Nutrition Is Ineffective for Patients With Severe Alcoholic Hepatitis Treated With Corticosteroids
- Author
-
Moreno, Christophe, Deltenre, Pierre, Senterre, Christelle, Louvet, Alexandre, Gustot, Thierry, Bastens, Boris, Hittelet, Axel, Piquet, Marie-Astrid, Laleman, Wim, Orlent, Hans, Lasser, Luc, Sersté, Thomas, Starkel, Peter, De Koninck, Xavier, Negrin Dastis, Sergio, Delwaide, Jean, Colle, Isabelle, de Galocsy, Chantal, Francque, Sven, Langlet, Philippe, Putzeys, Virginie, Reynaert, Hendrik, Degré, Delphine, and Trépo, Eric more...
- Published
- 2016
- Full Text
- View/download PDF
8. Viral clade is associated with severity of symptomatic genotype 3 Hepatitis E virus infections in Belgium, 2010-2018.
- Author
-
UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service de gastro-entérologie, Peeters, Michael, Schenk, Julie, De Somer, Thomas, Roskams, Tania, Locus, Tatjana, Klamer, Sofieke, Subissi, Lorenzo, Suin, Vanessa, Delwaide, Jean, Stärkel, Peter, De Maeght, Stéphane, Willems, Philippe, Colle, Isabelle, Van Hoof, Marc, Van Acker, Jos, Van Steenkiste, Christophe, Moreno, Christophe, Janssens, Filip, Reynders, Marijke, Steverlynck, Matthias, Verlinden, Wim, Lasser, Luc, de Galocsy, Chantal, Geerts, Anja, Maus, Jeroen, Gallant, Marie, Van Outryve, Steven, Marot, Astrid, Reynaert, Hendrik, Decaestecker, Jochen, Bottieau, Emmanuel, Schreiber, Jonas, Mulkay, Jean-Pierre, de Goeij, Sébastien, Salame, Mikhaël, Dooremont, Diederik, Dastis, Sergio Negrín, Boes, Juul, Nijs, Jochen, Beyls, Jan, Hens, Niel, Nevens, Frederik, Van Gucht, Steven, Vanwolleghem, Thomas, Belgian Association for the Study of the Liver, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service de gastro-entérologie, Peeters, Michael, Schenk, Julie, De Somer, Thomas, Roskams, Tania, Locus, Tatjana, Klamer, Sofieke, Subissi, Lorenzo, Suin, Vanessa, Delwaide, Jean, Stärkel, Peter, De Maeght, Stéphane, Willems, Philippe, Colle, Isabelle, Van Hoof, Marc, Van Acker, Jos, Van Steenkiste, Christophe, Moreno, Christophe, Janssens, Filip, Reynders, Marijke, Steverlynck, Matthias, Verlinden, Wim, Lasser, Luc, de Galocsy, Chantal, Geerts, Anja, Maus, Jeroen, Gallant, Marie, Van Outryve, Steven, Marot, Astrid, Reynaert, Hendrik, Decaestecker, Jochen, Bottieau, Emmanuel, Schreiber, Jonas, Mulkay, Jean-Pierre, de Goeij, Sébastien, Salame, Mikhaël, Dooremont, Diederik, Dastis, Sergio Negrín, Boes, Juul, Nijs, Jochen, Beyls, Jan, Hens, Niel, Nevens, Frederik, Van Gucht, Steven, Vanwolleghem, Thomas, and Belgian Association for the Study of the Liver more...
- Abstract
Hepatitis E virus (HEV) genotype (gt) 3 infections are prevalent in high income countries and display a wide spectrum of clinical presentations. Host - but not viral - factors are reported to be associated with worse clinical outcomes. Demographic, clinical and biochemical data of laboratory confirmed HEV infections (by PCR and/or a combination of IgM and IgG serology) at the Belgian National Reference Centre between January 2010 and June 2018 were collected using standardised case report forms. Genotyping was based on HEV Open Reading Frame 2 sequences. Serum CXCL10 levels were measured by a magnetic bead-based assay. H&E staining was performed on liver biopsies. 274 HEV-infected patients were included. Subtype assignment was possible for 179/218 viremic cases, confirming gt3 as dominant with an almost equal representation of clades abchijklm and efg. An increased hospitalisation rate and higher peak serum levels of alanine aminotransferase, bilirubin and alkaline phosphatase were found in clade efg infected patients in univariate analyses. In multivariable analyses, clade efg infections remained more strongly associated with severe disease presentation than any of the previously identified host risk factors. It associated with a 2·1-fold higher risk of hospitalisation (95% CI=1·1-4·4, p-value (p)=0·034) and with a 68·2% fold higher peak of bilirubin levels (95% CI=13·3-149·9, p=0·010), independently of other factors included in the model. In addition, acute clade efg infections were characterised by higher serum CXCL10 levels (p = 0·0005) and a more pronounced liver necro-inflammatory activity (p = 0·022). In symptomatic HEV gt3 infections, clade efg is associated with a more severe disease presentation, higher serum CXCL10 levels and liver necro-inflammatory activity, irrespective of known host risk factors. Hepatitis E virus genotype 3 infections are prevalent in high income countries and display a wide spectrum of clinical presentations. We here analysed the ro more...
- Published
- 2022
9. Enteral nutrition with or without N-acetylcysteine in the treatment of severe acute alcoholic hepatitis: A randomized multicenter controlled trial
- Author
-
Moreno, Christophe, Langlet, Philippe, Hittelet, Axel, Lasser, Luc, Degré, Delphine, Evrard, Sylvie, Colle, Isabelle, Lemmers, Arnaud, Devière, Jacques, and Le Moine, Olivier
- Published
- 2010
- Full Text
- View/download PDF
10. A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation
- Author
-
UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - SSS/IREC/MEDA - Pôle de médecine aiguë, UCL - (SLuc) Service de soins intensifs, UCL - (SLuc) Service de gastro-entérologie et hépatologie pédiatrique, Nevens, Frederik, Gustot, Thierry, Laterre, Pierre-François, Lasser, Luc L., Haralampiev, Lyudmil E., Vargas, Victor, Lyubomirova, Desislava, Albillos, Agustin, Najimi, Mustapha, Michel, Sébastien, Stoykov, Ivaylo, Gordillo, Noelia, Vainilovich, Yelena, Barthel, Virginie, Clerget-Chossat, Nathalie, Sokal, Etienne, UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - SSS/IREC/MEDA - Pôle de médecine aiguë, UCL - (SLuc) Service de soins intensifs, UCL - (SLuc) Service de gastro-entérologie et hépatologie pédiatrique, Nevens, Frederik, Gustot, Thierry, Laterre, Pierre-François, Lasser, Luc L., Haralampiev, Lyudmil E., Vargas, Victor, Lyubomirova, Desislava, Albillos, Agustin, Najimi, Mustapha, Michel, Sébastien, Stoykov, Ivaylo, Gordillo, Noelia, Vainilovich, Yelena, Barthel, Virginie, Clerget-Chossat, Nathalie, and Sokal, Etienne more...
- Abstract
BACKGROUND & AIMS: Human allogeneic liver-derived progenitor cells (HALPC, HepaStem®; Promethera Biosciences, Mont-Saint-Guibert, Belgium) are an advanced therapy medicinal product that could potentially alleviate systemic inflammation and ameliorate liver function in patients with acute-on-chronic liver failure (ACLF) or acute decompensation of cirrhosis (AD). METHODS: This open-label phase II study was conducted in 9 centres in Belgium, Spain, and Bulgaria between 2016 and 2019. The primary objective was to assess the safety of HALPC therapy up to Day 28 and the secondary objectives were to assess its safety and preliminary efficacy up to Month 3. RESULTS: The 24 treated patients (mean age: 51 years) were mostly male with an alcoholic cirrhosis. On pre-infusion Day 1, 15 patients had ACLF and 9 patients had AD. Two of the 3 initial patients treated with high HALPC doses (∼5×106 cells/kg body weight [BW]) had severe adverse bleeding events attributed to treatment. In 21 patients subsequently treated with lower HALPC doses (0.6 or 1.2×106 cells/kg BW, 1 or 2 times 7 days apart), no serious adverse events were related to treatment, and the other adverse events were in line with those expected in patients with ACLF and AD. Overall, markers of systemic inflammation and altered liver function decreased gradually for the surviving patients. The Day-28 and Month-3 survival rates were 83% (20/24) and 71% (17/24), and at Month 3, no patient had ACLF. CONCLUSIONS: The treatment of patients with ACLF or AD with up to 2 doses of 1.2×106 HALPC/kg BW appeared safe. The results of this study support the initiation of a proof-of-concept study in a larger cohort of patients with ACLF to further confirm the safety and evaluate the efficacy of HALPC therapy. CLINICAL TRIALS REGISTRATION: EudraCT 2016-001177-32. LAY SUMMARY: Patients with liver cirrhosis may suffer from the rapid onset of organ failure or multiple organ failure associated with a high risk of death in the short term. T more...
- Published
- 2021
11. Impact of intensive enteral nutrition in association with corticosteroids in the treatment of severe alcoholic hepatitis: a multicenter randomized controlled trial: 141
- Author
-
Moreno, Christophe, Trépo, Eric, Louvet, Alexandre, Degré, Delphine, Bastens, Boris, Hittelet, Axel, Piquet, Marie-Astrid, Laleman, Wim, Orlent, Hans, Lasser, Luc, Sersté, Thomas, Starkel, Peter, Dekoninck, Xavier, Dastis, Sergio Negrin, Delwaide, Jean, Colle, Isabelle, de Galocsy, Chantal, Francque, Sven M., Langlet, Philippe, Putzeys, Virginie, Reynaert, Hendrik, Gustot, Thierry, and Deltenre, Pierre more...
- Published
- 2014
12. Behandeling van het 'buried bumper syndrome': case-report en overzicht van de literatuur
- Author
-
François, Silke, De Koster, Erik, Lasser, Luc, and gastro-enterologie
- Abstract
In patients with a long-term insufficiency of oral intake, a percutaneous endoscopic gastrostomy (PEG) is a widely used method of nutrition delivery. PEG complication rates vary from 0.4 to 22.5%. One of the major complications is a buried bumper syndrome, where the internal fixation device migrates alongside the stoma tract out of the stomach. Because of the complications (gastro-intestinal bleedings) perforation, peritonitis, intra-abdominal and abdominal wall abscesses), which can be fatal, a definitive removal must be executed. This is mostly managed through an endoscopic or a surgical treatment. In this article, the medical history of a 58-yearold lady with a buried bumper, which was successfully removed by the endoscopically snare push-and-pull technique, is discussed. more...
- Published
- 2020
13. Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes
- Author
-
Van Hees, S., Bourgeois, S., Van Vlierberghe, H., Sersté, T., Francque, S., Michielsen, P., Sprengers, D., Reynaert, H., Henrion, J., Negrin Dastis, S., Delwaide, J., Lasser, L., Decaestecker, J., Orlent, H., Janssens, F., Robaeys, G., Colle, I., Stärkel, P., Moreno, C., Nevens, F., Vanwolleghem, T., Van Hees, Stijn, Bourgeois, Stefan, Van Vlierberghe, Hans, Sersté, Thomas, Francque, Sven, Michielsen, Peter, Sprengers, Dirk, Reynaert, Hendrik, Henrion, Jean, Negrin‐Dastis, Sergio, Delwaide, Jean, Lasser, Luc, Decaestecker, Jochen, Orlent, Hans, Janssens, Filip, Robaeys, Geert, Colle, Isabelle, Stärkel, Peter, Moreno, Christophe, Nevens, Frederik, Vanwolleghem, Thomas, Nuclear Medicine, Liver Cell Biology, Laboratory of Molecullar and Cellular Therapy, Basic (bio-) Medical Sciences, Faculty of Medicine and Pharmacy, Gastroenterology, Gastroenterology & Hepatology, and Belgian NA Stop Study Group more...
- Subjects
Male ,0301 basic medicine ,HBsAg ,Antibodies, Viral ,Gastroenterology ,Cohort Studies ,Fatal Outcome ,0302 clinical medicine ,Recurrence ,HEPATOCELLULAR-CARCINOMA ,E-ANTIGEN ,Medicine and Health Sciences ,Pharmacology (medical) ,Hepatitis B e Antigens ,ENTECAVIR TREATMENT ,Pharmacology. Therapy ,Nucleosides ,Middle Aged ,Hepatitis B ,PREDICTS ,Treatment Outcome ,HBeAg ,Seroconversion ,Hepatocellular carcinoma ,SUSTAINED VIROLOGICAL RESPONSE ,Cohort ,Original Article ,Female ,030211 gastroenterology & hepatology ,CLINICAL-PRACTICE GUIDELINES ,Cohort study ,Adult ,Hepatitis B virus ,medicine.medical_specialty ,DISCONTINUATION ,VIRUS-INFECTION ,GAMMA-GLUTAMYL-TRANSFERASE ,Antiviral Agents ,03 medical and health sciences ,Hepatitis B, Chronic ,SDG 3 - Good Health and Well-being ,Fatal Outcomes from Stopping Nucleoside Analogues in Hepatitis B ,Internal medicine ,SEROCONVERSION ,medicine ,Humans ,CONSOLIDATION THERAPY ,Hepatology ,business.industry ,medicine.disease ,digestive system diseases ,Discontinuation ,030104 developmental biology ,Withholding Treatment ,Human medicine ,business - Abstract
Background: Stopping nucleos(t)ide analogues (NA) after hepatitis B e antigen (HBeAg) seroconversion is associated with high relapse rates in Asian patients, but data in Caucasian cohorts are scarce. Clinical course, outcomes and immunological aspects of chronic hepatitis B infections differ substantially between distinct ethnicities. Aim: The aim of this study was to determine relapse rates, factors predicting relapse and clinical outcomes after nucleos(t)ide analogue cessation in a large, predominantly Caucasian cohort of chronic hepatitis B patients with nucleos(t)ide analogue-induced HBeAg seroconversion. Methods: This is a nationwide observational cohort study including HBeAg positive, mono-infected chronic hepatitis B patients with nucleos(t)ide analogue-induced HBeAg seroconversion from 18 centres in Belgium. Results: A total of 98 patients with nucleo(s)tide analogue-induced HBeAg seroconversion were included in the study. Of the 62 patients who stopped treatment after a median consolidation treatment of 8 months, 30 relapsed. Higher gamma-glutamyl transferase levels at both treatment initiation (HR 1.004; P = 0.001 per unit increment) and HBeAg seroconversion (HR 1.006; P = 0.013 per unit increment) were associated with an increased risk of clinically significant relapse in a multivariate Cox regression model. Treatment cessation led to liver-related death in 2 patients, of whom one showed a severe flare. Of the patients who continued treatment after HBeAg seroconversion, none relapsed or developed severe hepatic outcomes. Conclusion: Treatment withdrawal in Caucasian chronic hepatitis B patients after nucleos(t)ide analogue-induced HBeAg seroconversion results in viral relapses in more than half of patients with potential fatal outcomes. These real-world data further lend support to preferentially continue NA treatment after HBeAg seroconversion until HBsAg loss. Foundation Against Cancer Belgium, Grant/Award Number: 2014-087 more...
- Published
- 2018
- Full Text
- View/download PDF
14. FRI-550 - ACLF course profiles over screening period in the phase IIb DHELIVER study
- Author
-
Nevens, Frederik, Thabut, Dominique, Rudler, Marika, Adrien, Lannes, Lasser, Luc, Brjalin, Vadim, Pageaux, Georges-Philippe, Janczewska, Ewa, Toniutto, Pierluigi, Martinez, Javier, Reiberger, Thomas, Sánchez-Delgado, Jordi, Vargas, Victor, Gustot, Thierry, Maasoumy, Benjamin, Grønbæk, Henning, Bruns, Tony, Bureau, Christophe, Stardelova, Kalina Grivcheva, Pavlova, Desislava, Nikolov, Ivaylo, Katzarov, Krum, Draganov, Ventseslav, Monterde, Vanesa Bernal, Gordillo, Noelia, Vainilovich, Yelena, Najimi, Mustapha, Barthel, Virginie, Lin, Frederic, and Sokal, Etienne more...
- Published
- 2023
- Full Text
- View/download PDF
15. Good long-term outcome of Budd-Chiari syndrome with a step-wise management
- Author
-
Seijo, Susana, Plessier, Aurelie, Hoekstra, Jildou, Dell'Era, Alessandra, Mandair, Dalvinder, Rifai, Kinan, Trebicka, Jonel, Morard, Isabelle, Lasser, Luc, Abraldes, Juan G., Darwish Murad, Sarwa, Heller, Jörg, Hadengue, Antoine, Primignani, Massimo, Elias, Elwyn, Janssen, Harry L.A., Valla, Dominique C., and Garcia-Pagan, Juan-Carlos more...
- Published
- 2013
- Full Text
- View/download PDF
16. Hepatitis E virus genotype 3 subtype dependent clinical outcomes in Belgium 2010–2018
- Author
-
Peeters, Michael, primary, De Somer, Thomas, additional, Klamer, Sofieke, additional, Nevens, Frederik, additional, Delwaide, Jean-Pierre, additional, Stärkel, Peter, additional, Willems, Philippe, additional, De Maeght, Stéphane, additional, Moreno, Christophe, additional, Van Hoof, Marc, additional, Colle, Isabelle, additional, Van Steenkiste, Christophe, additional, Janssens, Filip, additional, Van Acker, Jos, additional, Marot, Astrid, additional, Bottieau, Emmanuel, additional, Reynders, Marijke, additional, De Galocsy, Chantal, additional, Lasser, Luc, additional, Steverlynck, Matthias, additional, Maus, Jeroen, additional, Verlinden, Wim, additional, Geerts, Anja, additional, Gallant, Marie, additional, Steven, Van Outryve, additional, Reynaert, Hendrik, additional, Mulkay, Jean-Pierre, additional, Decaestecker, Jochen, additional, Suin, Vanessa, additional, Negrin-Dastis, Sergio, additional, Beyls, Jan, additional, Nijs, Jochen, additional, Boes, Juul, additional, Van Gucht, Steven, additional, and Vanwolleghem, Thomas, additional more...
- Published
- 2020
- Full Text
- View/download PDF
17. Giant fibrovascular polyp of the esophagus
- Author
-
François, Silke, primary, Waldbillig, Claire, additional, Lasser, Luc, additional, Ngassa, Michèle, additional, and Khamaktchian, Mehdi, additional
- Published
- 2020
- Full Text
- View/download PDF
18. Acute Portal Vein Thrombosis Unrelated to Cirrhosis: A Prospective Multicenter Follow-Up Study
- Author
-
Plessier, Aurelie, Darwish-Murad, Sarwa, Hernandez-Guerra, Manuel, Consigny, Yann, Fabris, Federica, Trebicka, Jonel, Heller, Jorg, Morard, Isabelle, Lasser, Luc, Langlet, Philippe, Denninger, Marie-Hélène, Vidaud, Dominique, Condat, Bertrand, Hadengue, Antoine, Primignani, Massimo, Garcia-Pagan, Juan-Carlos, Janssen, Harry L. A., and Valla, Dominique more...
- Published
- 2010
- Full Text
- View/download PDF
19. Etiology, Management, and Outcome of the Budd-Chiari Syndrome
- Author
-
Murad, Sarwa Darwish, Plessier, Aurelie, Hernandez-Guerra, Manuel, Fabris, Federica, Eapen, Chundamannil E., Bahr, Matthias J., Trebicka, Jonel, Morard, Isabelle, Lasser, Luc, Heller, Joerg, Hadengue, Antoine, Langlet, Philippe, Miranda, Helena, Primignani, Massimo, Elias, Elwyn, Leebeek, Frank W., Rosendaal, Frits R., Garcia-Pagan, Juan-Carlos, Valla, Dominique C., and Janssen, Harry L.A. more...
- Published
- 2009
20. Safety and tolerability of liver-derived sem cells (Hepastem TM) infused in patients with acute on chronic liver failure (ACLF) or acute decompensation (AD) at risk of developing ACLF: a european phase I/IIa open labelled study
- Author
-
Nevens, Frederik, Laterre, Pierre-François, Lasser, Luc, Haralampiev, Lyudmil, Vargas, Victor, Lyubomirova, Desislava, Albillos, Agustin, Barthel, Virginie, Clerget, Nathalie, Sokal, Etienne, The Liver Meeting AASLD (American Association of the Study of Liver Diseases), UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Service de gastro-entérologie et hépatologie pédiatrique, and UCL - (SLuc) Service de soins intensifs more...
- Published
- 2019
21. Safety and tolerability of liver-derived stem cells (HepaStem) infused in patients with acute-on-chronic liver failure or acute decompensation: a European phase I/IIa open-labelled study
- Author
-
Nevens, Frederik, Gustot, Thierry, Laterre, Pierre-François, Lasser, Luc, Haralampiev, Lyudmil Enev, Vargas, Victor, Barthel, Virginie, Clerget-Chossat, Nathalie, Sokal, Etienne, The International Liver Congress (EASL), UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, and UCL - (SLuc) Service de gastro-entérologie et hépatologie pédiatrique more...
- Published
- 2019
22. Safety and tolerability of liver-derived sem cells (Hepastem TM) infused in patients with acute on chronic liver failure (ACLF) or acute decompensation (AD) at risk of developing ACLF: a european phase I/IIa open labelled study
- Author
-
UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Service de gastro-entérologie et hépatologie pédiatrique, UCL - (SLuc) Service de soins intensifs, Nevens, Frederik, Laterre, Pierre-François, Lasser, Luc, Haralampiev, Lyudmil, Vargas, Victor, Lyubomirova, Desislava, Albillos, Agustin, Barthel, Virginie, Clerget, Nathalie, Sokal, Etienne, The Liver Meeting AASLD (American Association of the Study of Liver Diseases), UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Service de gastro-entérologie et hépatologie pédiatrique, UCL - (SLuc) Service de soins intensifs, Nevens, Frederik, Laterre, Pierre-François, Lasser, Luc, Haralampiev, Lyudmil, Vargas, Victor, Lyubomirova, Desislava, Albillos, Agustin, Barthel, Virginie, Clerget, Nathalie, Sokal, Etienne, and The Liver Meeting AASLD (American Association of the Study of Liver Diseases) more...
- Published
- 2019
23. New Concepts in Liver Regeneration Mechanisms in Human Severe Alcoholic Steatohepatitis
- Author
-
Lejeune, Adrienne, Starkel, Peter, Louvet, Alexandre, Hittelet, Axel, Bazille, Celine, Bastens, Boris, Orient, Hans, Lasser, Luc I., Dekoninck, Xavier, Dastis, Sergio Negrin, Delwaide, Jean, Anja, Geerts, De Galocsy, Chantal, Putzeys, Virginie, Langlet, Phillippe, Reynaert, Hendrik, Francque, Sven M., Komuta, Mina, Lanthier, Nicolas, Basic (bio-) Medical Sciences, Gastroenterology, Laboratory of Molecullar and Cellular Therapy, and Liver Cell Biology more...
- Published
- 2018
24. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial
- Author
-
Merle, Philippe, primary, Blanc, Jean-Frederic, additional, Phelip, Jean-Marc, additional, Pelletier, Gilles, additional, Bronowicki, Jean-Pierre, additional, Touchefeu, Yann, additional, Pageaux, Georges, additional, Gerolami, René, additional, Habersetzer, François, additional, Nguyen-Khac, Eric, additional, Casadei-Gardini, Andrea, additional, Borbath, Ivan, additional, Tran, Albert, additional, Wege, Henning, additional, Saad, Amr Shafik, additional, Colombo, Massimo, additional, Abergel, Armand, additional, Richou, Carine, additional, Waked, Imam, additional, Yee, Nelson S, additional, Molé, Audrey, additional, Attali, Pierre, additional, Le Boulicaut, Julie, additional, Vasseur, Bérangère, additional, Moussata, Driffa, additional, Grangé, Jean-Didier, additional, Ratziu, Vlad, additional, Khemissa-Akouz, Faiza, additional, Regnault, Hélène, additional, Dauvois, Barbara, additional, Zarski, Jean-Pierre, additional, Ollivier-Hourmand, Isabelle, additional, Manfredi, Sylvain, additional, Debette-Gratien, Marilyne, additional, Gangloff, Alice, additional, Fontanges, Thierry, additional, Baron, Aurore, additional, Bouattour, Mohamed, additional, Vincent, Julie, additional, Sieghart, Wolfgang, additional, Maieron, Andreas, additional, Peeters, Marc, additional, Delwaide, Jean, additional, Lasser, Luc, additional, Berg, Thomas, additional, Schultheiß, Michael, additional, Zipprich, Alexander, additional, Trojan, Joerg, additional, Ehmer, Ursula, additional, Luppi, Gabriele, additional, Luca, Giovanni, additional, Tamberi, Stefano, additional, Amoroso, Domenico, additional, Alabiso, Oscar, additional, Buonadonna, Angela, additional, Toniutto, Pierluigi, additional, Tamburini, Emiliano, additional, Cubillo, Antonio, additional, Muñoz, Andrés, additional, Guillén, Carmen, additional, Sánchez, Gloria, additional, Manzano, Hermini, additional, Navarro, Victor, additional, Ales, Inmaculada, additional, Massuti, Bartomeu, additional, Dank, Magdolna, additional, Bodoky, György, additional, Kahan, Zsuzsanna, additional, Horváth, Zsolt, additional, Gabrail, Nashat, additional, Ozer, Howard, additional, Galanopoulos, Christos, additional, Hauke, Ralph, additional, Raj, Moses, additional, Harputluoglu, Hakan, additional, Sevinc, Alper, additional, Goker, Erdem, additional, Coker, Ahmet, additional, Yalcin, Suayib, additional, Ali, Muhammet, additional, Ata, Ozlem, additional, Tugba, Ilkay, additional, El Kassas, Mohammed, additional, Abdel, Amr, additional, Wakid, Imam, additional, Shamaa, Sameh, additional, El Lahlouby, Nasr, additional, Kohail, Hanaa, additional, Makarem, Jawad, additional, Chehade, Issam, additional, Farhat, Fadi, additional, López, Carlos, additional, and Marín, Miguel, additional more...
- Published
- 2019
- Full Text
- View/download PDF
25. FRI-221-Management of drug-drug interactions in chronic hepatitis C patients treated with second generation direct acting antivirals in Belgium
- Author
-
Bourgeois, Stefan, primary, Mulkay, Jean-Pierre, additional, Cool, Mike, additional, Xavier, Verhelst, additional, Robaeys, Geert, additional, Lasser, Luc, additional, Lefebvre, Veronique, additional, Colle, Isabelle, additional, Steenkiste, Christophe Van, additional, Decaestecker, Jochen, additional, Coulon, Stephanie, additional, Venken, Katrien, additional, and Vanwolleghem, Thomas, additional more...
- Published
- 2019
- Full Text
- View/download PDF
26. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis
- Author
-
De Gottardi, Andrea, Trebicka, Jonel, Klinger, Christoph, Plessier, Aurélie, Seijo, Susana, Terziroli, Benedetta, Magenta, Lorenzo, Semela, David, Buscarini, Elisabetta, Langlet, Philippe, Görtzen, Jan, Puente, Angela, Müllhaupt, Beat, Navascuès, Carmen, Nery, Filipe, Deltenre, Pierre, Turon, Fanny, Engelmann, Cornelius, Arya, Rupen, Caca, Karel, Peck‐Radosavljevic, Markus, Leebeek, Frank W. G., Valla, Dominique, Garcia‐Pagan, Juan Carlos, Grønbæk, Henning, Beer, Jürg‐Hans, Genescà, Joan, Hidalgo, Canete, Vila, Carmen, Mihailovic, Jelena, Piscaglia, Fabio, Lasser, Luc, Fernandez‐Bermejo, Miguel, Procopet, Bogdan, Schouten, Jeoffrey, Spahr, Laurent, Sanchez, José Louis, Zipprich, Alexander, Sekhar, Mallika, Hernandez‐Guerra, Manuel, Laguna, La, Nevens, Frederik, Ferreira, Carlos Noronha, Heneghan, Michael, Albillos, Agustin, Llop, Elba, Dell'Era, Alessandra, La Mura, Vincenzo, Primignani, Massimo, Senzolo, Marco, Escarda, Ana, Mallorca, Palma, Riggio, Oliviero, Murad, Sarwa Darwish, Haas, Stephan, Bureau, Christophe, Berenguer, Marina, De Gottardi, Andrea, Trebicka, Jonel, Klinger, Christoph, Plessier, Aurélie, Seijo, Susana, Terziroli, Benedetta, Magenta, Lorenzo, Semela, David, Buscarini, Elisabetta, Langlet, Philippe, Görtzen, Jan, Puente, Angela, Müllhaupt, Beat, Navascuès, Carmen, Nery, Filipe, Deltenre, Pierre, Turon, Fanny, Engelmann, Corneliu, Arya, Rupen, Caca, Karel, Peck-Radosavljevic, Marku, Leebeek, Frank W. G., Valla, Dominique, Garcia-Pagan, Juan Carlo, on behalf of the VALDIG Investigators: [.., Fabio Piscaglia, ], University of Zurich, and Hematology more...
- Subjects
Budd-Chiari syndrome ,medicine.medical_specialty ,Deep vein ,610 Medicine & health ,03 medical and health sciences ,Anticoagulation ,0302 clinical medicine ,Journal Article ,medicine ,Portal vein thrombosi ,Cirrhosis ,Portal vein thrombosis ,Hepatology ,Rivaroxaban ,Cirrhosi ,business.industry ,medicine.disease ,Thrombosis ,3. Good health ,Surgery ,Venous thrombosis ,medicine.anatomical_structure ,10219 Clinic for Gastroenterology and Hepatology ,Splanchnic vein thrombosis ,030220 oncology & carcinogenesis ,030211 gastroenterology & hepatology ,Apixaban ,2721 Hepatology ,Liver function ,business ,medicine.drug - Abstract
BACKGROUND: Direct-acting oral anticoagulants (DOACs) are used in patients with splanchnic vein thrombosis (SVT) and cirrhosis, but evidence for safety and efficacy in this setting is limited. Our aim was to identify indications and reasons for starting or switching to DOACs and to report adverse effects, complications and short-term outcome.METHODS: Data collection including demographic information, laboratory values, treatment and complications through the Vascular Liver Disease Interest Group Consortium.RESULTS: Forty-five centres (90%) of the consortium completed the initial eCRF. We report here a series of 94 patients from 17 centres. Thirty-six patients (38%) had cirrhosis. Child-Pugh score was 6 (range 5-8), and MELD score 10.2 (range 6-19). Indications for anticoagulation were splanchnic vein thrombosis (75%), deep vein thrombosis (5%), atrial fibrillation (14%) and others (6%). DOACs used were rivaroxaban (83%), dabigatran (11%) and apixaban (6%). Patients were followed up for a median duration of 15 months (cirrhotic) and 26.5 months (non-cirrhotic). Adverse events occurred in 17% of patients and included one case of recurrent portal vein thrombosis and five cases of bleeding. Treatment with DOACs was stopped in three cases. The major reasons for choosing DOACs were no need for monitoring or inadequacy of INR to guide anticoagulation in cirrhotic patients. Renal and liver function did not change during treatment.CONCLUSIONS: A consistent number of patients with SVT and/or cirrhosis are currently treated with DOACs, which seem to be effective and safe. These data provide a basis for performing randomized clinical trials of DOACs vs. low molecular weight heparin or vitamin K antagonists. more...
- Published
- 2017
- Full Text
- View/download PDF
27. Cessation of Nucleos(t)ide Analogue treatment after HBeAg seroconversion is associated with a 4-fold increased risk of relapse in cirrhotic compared to non-cirrhotic patients
- Author
-
Van Hees, Stijn, Bourgeois, Stefan, Van Vlierberghe, Hans, Sersté, Thomas, Francque, Sven, Michielsen, Peter P., Dirk, Sprengers, Reynaert, Hendrik, Henrion, Jean, Dastis, Sergio Negrin, Delwaide, Jean, Lasser, Luc, Decaestecker, Jochen, Orlent, Hans, Janssens, Filip, Robaeys, Geert, Colle, Isabelle, Starkel, Peter, Moreno, Christophe, Nevens, Frederik, Vanwolleghem, Thomas, Liver Cell Biology, Laboratory of Molecullar and Cellular Therapy, and Basic (bio-) Medical Sciences more...
- Abstract
Isabelle Colle - Consulting: Promethera; Grant/Research Support: abbvie; Patent Held/Filed: Trombogenics; Speaking and Teaching: BMS Christophe Moreno - Consulting: Abbvie, Janssen, Gilead, BMS, MSD; Grant/Research Support: Janssen, Gilead, Roche, Astellas, Abbvie Frederik Nevens - Consulting: MSD, CAF, Intercept, Gore, BMS, Abbvie, Novartis, Durect, Janssens-Cilag, Ono Pharma, Promethera Biosciences, Gilead; Grant/Research Support: Ferring, Roche, Astellas, Novartis, Janssen-Cilag, Abbvie, Gilead more...
- Published
- 2017
28. GS-16-Safety and tolerability of liver-derived stem cells (HepaStem) infused in patients with acute-on-chronic liver failure or acute decompensation: a European phase I/IIa open-labelled study
- Author
-
Barthel Virginie, Haralampiev Lyudmil Enev, Gustot Thierry, Etienne Sokal, Nevens Frederik, Vargas Victor, Laterre Pierre-François, Nathalie Clerget-Chossat, and Lasser Luc
- Subjects
medicine.medical_specialty ,Hepatology ,Tolerability ,business.industry ,Internal medicine ,Medicine ,Decompensation ,Acute on chronic liver failure ,In patient ,business ,Gastroenterology - Published
- 2019
- Full Text
- View/download PDF
29. Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium
- Author
-
UCL - (SLuc) Service de gastro-entérologie, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, Degré, Delphine, Sersté, Thomas, Lasser, Luc, Delwaide, Jean, Starkel, Peter, Laleman, Wim, Langlet, Philippe, Reynaert, Hendrik, Bourgeois, Stefan, Vanwolleghem, Thomas, Negrin Dastis, Sergio, Gustot, Thierry, Geerts, Anja, Van Steenkiste, Christophe, de Galocsy, Chantal, Lepida, Antonia, Orlent, Hans, Moreno, Christophe, Jhaveri, Ravi, UCL - (SLuc) Service de gastro-entérologie, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, Degré, Delphine, Sersté, Thomas, Lasser, Luc, Delwaide, Jean, Starkel, Peter, Laleman, Wim, Langlet, Philippe, Reynaert, Hendrik, Bourgeois, Stefan, Vanwolleghem, Thomas, Negrin Dastis, Sergio, Gustot, Thierry, Geerts, Anja, Van Steenkiste, Christophe, de Galocsy, Chantal, Lepida, Antonia, Orlent, Hans, Moreno, Christophe, and Jhaveri, Ravi more...
- Abstract
Introduction Hepatitis C virus (HCV) is a major global health issue and successful treatment has been associated with a reduction of risk of all-cause mortality. Advancements have been made in HCV treatment through the use of interferon-free regimens. Most trials have been conducted in HCV genotype (GT) 1 and data for interferon-free regimens in GT4 patients are limited. The aim of this study was to evaluate the safety and efficacy of sofosbuvir plus simeprevir in a real-world cohort of HCV GT4 patients with advanced fibrosis. Patients and Methods Eighty-seven GT4 treatment-naïve or –Interferon (IFN) ribavirin (RBV) experienced patients treated with sofosbuvir and simeprevir +/- ribavirin (RBV) were enrolled in this cohort study (41% severe fibrosis, 59% cirrhosis). Results Patients were 51.7% male, 78.2% IFN/RBV treatment-experienced, and 37.9% received RBV treatment. The overall sustained virologic response at least 12 weeks after treatment (SVR12) rate was 87.4% while patients treated with and without RBV had rates of 87.9% and 87% (p = 0.593), respectively, and patients with advanced fibrosis (F3) and patients with cirrhosis had SVR12 rates of 94.4% and 82.4% (p = 0.087), respectively. SVR12 rates in treatment-naïve patients and in IFN/RBV -experienced patients were 78.9% and 89.7% (p = 0.191), respectively. Treatment failure occurred most commonly in patients with cirrhosis and severe disease. The treatment was well tolerated and no patient died or discontinued treatment due to adverse events. Conclusions Sofosbuvir in combination with simeprevir +/- ribavirin in GT 4 HCV patients with advanced fibrosis achieved high SVR12 rates and was well tolerated. RBV did not appear to increase the rate of SVR12. more...
- Published
- 2017
30. Sofosbuvir in combination with simeprevir +/- ribavirin in genotype 4 hepatitis C patients with advanced fibrosis or cirrhosis: A real-world experience from Belgium
- Author
-
Degré, Delphine, Vanwolleghem, Thomas, Dastis, Sergio Negrin, Gustot, Thierry, Geerts, Anja, van Steenkiste, Christophe, De Galocsy, Chantal, Lepida, Antonia, Orlent, Hans, Moreno, Christophe, Serste, Thomas, Lasser, Luc, Delwaide, Jean, Starkel, Peter, Laleman, Wim, Langlet, Philippe, Reynaert, Hendrik, Bourgeois, Stefan, Degré, Delphine, Vanwolleghem, Thomas, Dastis, Sergio Negrin, Gustot, Thierry, Geerts, Anja, van Steenkiste, Christophe, De Galocsy, Chantal, Lepida, Antonia, Orlent, Hans, Moreno, Christophe, Serste, Thomas, Lasser, Luc, Delwaide, Jean, Starkel, Peter, Laleman, Wim, Langlet, Philippe, Reynaert, Hendrik, and Bourgeois, Stefan more...
- Abstract
Introduction: Hepatitis C virus (HCV) is a major global health issue and successful treatment has been associated with a reduction of risk of all-cause mortality. Advancements have been made in HCV treatment through the use of interferon-free regimens. Most trials have been conducted in HCV genotype (GT) 1 and data for interferon-free regimens in GT4 patients are limited. The aim of this study was to evaluate the safety and efficacy of sofosbuvir plus simeprevir in a real-world cohort of HCV GT4 patients with advanced fibrosis. Patients and Methods: Eighty-seven GT4 treatment-naïve or -Interferon (IFN) ribavirin (RBV) experienced patients treated with sofosbuvir and simeprevir +/- ribavirin (RBV) were enrolled in this cohort study (41% severe fibrosis, 59% cirrhosis). Results: Patients were 51.7% male, 78.2% IFN/RBV treatment-experienced, and 37.9% received RBV treatment. The overall sustained virologic response at least 12 weeks after treatment (SVR12) rate was 87.4% while patients treated with and without RBV had rates of 87.9% and 87% (p = 0.593), respectively, and patients with advanced fibrosis (F3) and patients with cirrhosis had SVR12 rates of 94.4% and 82.4% (p = 0.087), respectively. SVR12 rates in treatment-naïve patients and in IFN/RBV -experienced patients were 78.9% and 89.7% (p = 0.191), respectively. Treatment failure occurred most commonly in patients with cirrhosis and severe disease. The treatment was well tolerated and no patient died or discontinued treatment due to adverse events. Conclusions: Sofosbuvir in combination with simeprevir +/- ribavirin in GT 4 HCV patients with advanced fibrosis achieved high SVR12 rates and was well tolerated. RBV did not appear to increase the rate of SVR12., SCOPUS: ar.j, info:eu-repo/semantics/published more...
- Published
- 2017
31. SAT409 - Hepatitis E virus genotype 3 subtype dependent clinical outcomes in Belgium 2010–2018
- Author
-
Peeters, Michael, De Somer, Thomas, Klamer, Sofieke, Nevens, Frederik, Delwaide, Jean-Pierre, Stärkel, Peter, Willems, Philippe, De Maeght, Stéphane, Moreno, Christophe, Van Hoof, Marc, Colle, Isabelle, Van Steenkiste, Christophe, Janssens, Filip, Van Acker, Jos, Marot, Astrid, Bottieau, Emmanuel, Reynders, Marijke, De Galocsy, Chantal, Lasser, Luc, Steverlynck, Matthias, Maus, Jeroen, Verlinden, Wim, Geerts, Anja, Gallant, Marie, Steven, Van Outryve, Reynaert, Hendrik, Mulkay, Jean-Pierre, Decaestecker, Jochen, Suin, Vanessa, Negrin-Dastis, Sergio, Beyls, Jan, Nijs, Jochen, Boes, Juul, Van Gucht, Steven, and Vanwolleghem, Thomas more...
- Published
- 2020
- Full Text
- View/download PDF
32. Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium
- Author
-
Degré, Delphine, primary, Sersté, Thomas, additional, Lasser, Luc, additional, Delwaide, Jean, additional, Starkel, Peter, additional, Laleman, Wim, additional, Langlet, Philippe, additional, Reynaert, Hendrik, additional, Bourgeois, Stefan, additional, Vanwolleghem, Thomas, additional, Negrin Dastis, Sergio, additional, Gustot, Thierry, additional, Geerts, Anja, additional, Van Steenkiste, Christophe, additional, de Galocsy, Chantal, additional, Lepida, Antonia, additional, Orlent, Hans, additional, and Moreno, Christophe, additional more...
- Published
- 2017
- Full Text
- View/download PDF
33. Alcohol intake increases the risk of HCC in hepatitis C virus-related compensated cirrhosis: A prospective study.
- Author
-
UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service de gastro-entérologie, Vandenbulcke, Hélène, Moreno, Christophe, Colle, Isabelle, Knebel, Jean-François, Francque, Sven, Sersté, Thomas, George, Christophe, de Galocsy, Chantal, Laleman, Wim, Delwaide, Jean, Orlent, Hans, Lasser, Luc, Trépo, Eric, Van Vlierberghe, Hans, Michielsen, Peter, van Gossum, Marc, de Vos, Marie, MAROT, Astrid, Doerig, Christopher, Henrion, Jean, Deltenre, Pierre, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service de gastro-entérologie, Vandenbulcke, Hélène, Moreno, Christophe, Colle, Isabelle, Knebel, Jean-François, Francque, Sven, Sersté, Thomas, George, Christophe, de Galocsy, Chantal, Laleman, Wim, Delwaide, Jean, Orlent, Hans, Lasser, Luc, Trépo, Eric, Van Vlierberghe, Hans, Michielsen, Peter, van Gossum, Marc, de Vos, Marie, MAROT, Astrid, Doerig, Christopher, Henrion, Jean, and Deltenre, Pierre more...
- Abstract
Whether alcohol intake increases the risk of complications in patients with HCV-related cirrhosis remains unclear. The aim of this study was to determine the impact of alcohol intake and viral eradication on the risk of hepatocellular carcinoma (HCC), decompensation of cirrhosis and death. Data on alcohol intake and viral eradication were prospectively collected in 192 patients with compensated HCV-related cirrhosis. 74 patients consumed alcohol (median alcohol intake: 15g/day); 68 reached viral eradication. During a median follow-up of 58months, 33 patients developed HCC, 53 experienced at least one decompensation event, and 39 died. The 5-year cumulative incidence rate of HCC was 10.6% (95% CI: 4.6-16.6) in abstainers vs. 23.8% (95% CI: 13.5-34.1) in consumers (p=0.087), and 2.0% (95% CI: 0-5.8) vs. 21.7% (95% CI: 14.2-29.2) in patients with and without viral eradication (p=0.002), respectively. The lowest risk of HCC was observed for patients without alcohol intake and with viral eradication (0%) followed by patients with alcohol intake and viral eradication (6.2% [95% CI: 0-18.4]), patients without alcohol intake and no viral eradication (15.9% [95% CI: 7.1-24.7]), and patients with alcohol intake and no viral eradication (29.2% [95% CI: 16.5-41.9]) (p=0.009). In multivariate analysis, lack of viral eradication and alcohol consumption were associated with the risk of HCC (hazard ratio for alcohol consumption: 3.43, 95% CI: 1.49-7.92, p=0.004). Alcohol intake did not influence the risk of decompensation or death. Light-to-moderate alcohol intake increases the risk of HCC in patients with HCV-related cirrhosis. Patient care should include measures to ensure abstinence. Whether alcohol intake increases the risk of complications in patients with HCV-related cirrhosis remains unclear. In this prospective study, light-to-moderate alcohol intake was associated with the risk of hepatocellular carcinoma in multivariate analysis. No patients who did not use alcohol and wh more...
- Published
- 2016
34. Sofosbuvir in combination with simeprevir plus /- ribavirin in genotype 4 hepatitis C patients with advanced fibrosis or cirrhosis: real-life experience from Belgium
- Author
-
Moreno, Christophe, Lasser, Luc, Delwaide, J., Starkel, Peter, Laleman, W, Langlet, Philippe, Reynaert, Hendrik, Bourgeois, Stefan, Dastis, Sergio Negrin, Gustot, Thierry, Moreno, Christophe, Lasser, Luc, Delwaide, J., Starkel, Peter, Laleman, W, Langlet, Philippe, Reynaert, Hendrik, Bourgeois, Stefan, Dastis, Sergio Negrin, and Gustot, Thierry more...
- Abstract
0, info:eu-repo/semantics/published
- Published
- 2015
35. Ethnic epidemiological profiles and antiviral therapy among patients infected with hepatitis C virus genotype 4 :A multicenter study from Belgium
- Author
-
Nkuize, Marcel, Mulkay, Jean-Pierre, Moreno, Christophe, Lasser, Luc, Michielsen, Peter, De Galocsy, Chantal, Scheen, Robert, Assene, Collins, de Lwaide, Jean, Nkuize, Marcel, Mulkay, Jean-Pierre, Moreno, Christophe, Lasser, Luc, Michielsen, Peter, De Galocsy, Chantal, Scheen, Robert, Assene, Collins, and de Lwaide, Jean more...
- Abstract
Background :Hepatitis C virus genotype 4 (HCV-4) is the most prevalent genotype in Central Africa. Aim :To compare epidemiology, clinical characteristics and any differences in access to HCV therapy in two populations of HCV-4 patients residing in Belgium. Methods :This multicenter study selected 473 HCV-4 patients from seven hospital databases and compared them according to ethnic origin, i.e. Black African (n = 331) or not (n = 142), for epidemiological, clinical, biological and histological characteristics. Interleukin 28B polymorphism (CC-genotype) was evaluated in a second cohort of 69 Black African and 30 non-Black African patients. Results :Compared to other patients, the Black African patients were more likely to be female and were older, commonly overweight, frequently had abnormal glucose metabolism and arterial hypertension ;they were less likely to have dyslipidemia, a history of alcohol consumption or ALT elevation. The route of infection was more frequently unknown in Black African than in other patients. Black African patients had more HCV-4 subtypes, were less frequently of IL28B CC-genotype and had less severe liver fibrosis. The proportion of patients who received antiviral treatment was similar in the two groups. Conclusion :In this Belgian cohort, patients with HCV-4 infection were more frequently of Black African origin than of other origin. Infected Black African patients were more commonly female, older at diagnosis, and had more co-morbidities than other patients ;they also had less advanced liver fibrosis than infected non-Black African patients and fewer had a CC genotype., SCOPUS: ar.j, info:eu-repo/semantics/published more...
- Published
- 2015
36. A lady with NASH and choreoathetosis
- Author
-
Ghys, Christophe, Kong, M.F., Glibert, Gerald, Lasser, Luc, Karmali, Rafik, Ghys, Christophe, Kong, M.F., Glibert, Gerald, Lasser, Luc, and Karmali, Rafik
- Abstract
We describe a case of acquired hepatocerebral degeneration (AHD) presenting with confusion and worsening memory problems since her discharge from the gastroenterology units. Cases of AHD are rare and are frequently confused with hepatic encephalopathy and Wilson's disease. There are no proven pharmacological therapies for AHD. Information regarding the effect of orthotopic liver transplant on AHD is limited and conflicting. Most patients eventually die from the systemic complications of cirrhotic liver failure including infection, hepatic coma and hepatocellular carcinoma., SCOPUS: ar.j, info:eu-repo/semantics/published more...
- Published
- 2015
37. Characteristics, treatment, and virologic responses of chronic hepatitis C patients treated with peginterferon alfa-2a and ribavirin in Belgium: A sub-analysis of the PROPHESYS study
- Author
-
UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (SLuc) Service de gastro-entérologie, UCL - (MGD) Service de gastro-entérologie, Mulkay, Jena-Pierre, Bourgeois, Stefan, Lasser, Luc, De Galocsy, Chantal, Tomasovic, Stephan, Horsmans, Yves, Van Vlierberghe, Hans, Belgian PROPHESYS investigators, Martinet, Jean-Paul, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (SLuc) Service de gastro-entérologie, UCL - (MGD) Service de gastro-entérologie, Mulkay, Jena-Pierre, Bourgeois, Stefan, Lasser, Luc, De Galocsy, Chantal, Tomasovic, Stephan, Horsmans, Yves, Van Vlierberghe, Hans, Belgian PROPHESYS investigators, and Martinet, Jean-Paul more...
- Abstract
Background and study aims: PROPHESYS was a prospective, international cohort study of monoinfected, treatment-naive chronic hepatitis C patients treated with a combination of peginterferon alfa-2a or alfa-2b and ribavirin. It included worldwide 7,163 patients from 19 countries (including 384 patients from Belgium alone) and demonstrated that sustained virologic response rates in the real world were similar to those achieved in well-controlled clinical trials. The objective of this sub-analysis was to present an overview of the baseline characteristics, anti-hepatitis C drug treatment, and virologic responses of the patients treated in Belgium, infected with HCV genotype 1, 2, 3, or 4, and administered peginterferon alfa-2a. Moreover, the impact of ribavirin dosage on the response to treatment was studied. Patients and methods: 356 patients were included in this subanalysis. All variables were summarized using descriptive statistics. Results: Compared to the published data of the whole study population (1), the Belgian data presented some significant differences in terms of genotype distribution and response to treatment (e.g. lower prevalence of HCV genotype 1 infection, lower virologic response rates in HCV genotype 2 patients). Deviations from existing recommendations were identified (e.g. higher dose of ribavirin in HCV genotype 2 or 3 patients). Patients who received less than 80% of the target dose of ribavirin experienced a significantly weaker response to treatment. Conclusion: This sub-analysis provided an interesting profile of the Belgian experience in the treatment of chronic hepatitis C. more...
- Published
- 2014
38. DRESS syndrome à la phénytoïne
- Author
-
Oliveira, Y.S. Y.S., Boulvin, Serge, Mba Angoue, Jean-Marie, Lasser, Luc, Parent, Alain, Iba Ba, Josaphat, Sadibi, L.C., Nzenze, Jean Raymond, Oliveira, Y.S. Y.S., Boulvin, Serge, Mba Angoue, Jean-Marie, Lasser, Luc, Parent, Alain, Iba Ba, Josaphat, Sadibi, L.C., and Nzenze, Jean Raymond more...
- Abstract
Summary Drug rash with eosinophilia and systemic symptoms (DRESS syndrome) in a severe cutaneous drug reaction, which can be life threatening. We report a 62-year-old man suffering from DRESS Syndrome 8 weeks after diphantoïne (Phenytoïne®) exposure. He had a skin eruption, liver involvement and hypereosinophilia. He fully recovered after drug withdrawal. © 2014 .Tous droits réservés., SCOPUS: ar.j, info:eu-repo/semantics/published more...
- Published
- 2014
39. Characteristics, treatment, and virologic responses of chronic hepatitis C patients treated with peginterferon alfa-2a and ribavirin in Belgium: A sub-analysis of the PROPHESYS study
- Author
-
Mulkay, Jean-Pierre, Bourgeois, Stefan, Lasser, Luc, De Galocsy, Chantal, Tomasovic, S., Horsmans, Y., van Vlierberghe, Han, Mulkay, Jean-Pierre, Bourgeois, Stefan, Lasser, Luc, De Galocsy, Chantal, Tomasovic, S., Horsmans, Y., and van Vlierberghe, Han more...
- Abstract
Background and study aims: PROPHESYS was a prospective, international cohort study of monoinfected, treatment-naive chronic hepatitis C patients treated with a combination of peginterferon alfa-2a or alfa-2b and ribavirin. It included worldwide 7,163 patients from 19 countries (including 384 patients from Belgium alone) and demonstrated that sustained virologic response rates in the real world were similar to those achieved in well-controlled clinical trials. The objective of this sub-analysis was to present an overview of the baseline characteristics, anti-hepatitis C drug treatment, and virologic responses of the patients treated in Belgium, infected with HCV genotype 1, 2, 3, or 4, and administered peginterferon alfa-2a. Moreover, the impact of ribavirin dosage on the response to treatment was studied. Patients and methods: 356 patients were included in this subanalysis. All variables were summarized using descriptive statistics. Results: Compared to the published data of the whole study population (1), the Belgian data presented some significant differences in terms of genotype distribution and response to treatment (e.g. lower prevalence of HCV genotype 1 infection, lower virologic response rates in HCV genotype 2 patients). Deviations from existing recommendations were identified (e.g. higher dose of ribavirin in HCV genotype 2 or 3 patients). Patients who received less than 80% of the target dose of ribavirin experienced a significantly weaker response to treatment. Conclusion: This sub-analysis provided an interesting profile of the Belgian experience in the treatment of chronic hepatitis C., SCOPUS: ar.j, info:eu-repo/semantics/published more...
- Published
- 2014
40. Impact of intensive enteral nutrition in association with corticosteroids in the treatment of severe alcoholic hepatitis: a multicenter randomized controlled trial
- Author
-
Moreno, Christophe, Trepo, Eric, Louvet, Alexandre, Degré, Delphine, Bastens, Boris, Hittelet, Axel-Benoit, Piquet, Marie-Astrid, Laleman, Wim, Orlent, Hans, Lasser, Luc, Serste, Thomas, Starkel, Peter, Dekoninck, Wouter, Dastis, Sergio Negrin, Delwaide, Jean, Colle, Isabelle, De Galocsy, Chantal, Francque, Sven, Langlet, Philippe, Putzeys, Virginie, Reynaert, Hendrik, Gustot, Thierry, Moreno, Christophe, Trepo, Eric, Louvet, Alexandre, Degré, Delphine, Bastens, Boris, Hittelet, Axel-Benoit, Piquet, Marie-Astrid, Laleman, Wim, Orlent, Hans, Lasser, Luc, Serste, Thomas, Starkel, Peter, Dekoninck, Wouter, Dastis, Sergio Negrin, Delwaide, Jean, Colle, Isabelle, De Galocsy, Chantal, Francque, Sven, Langlet, Philippe, Putzeys, Virginie, Reynaert, Hendrik, and Gustot, Thierry more...
- Abstract
0, info:eu-repo/semantics/published
- Published
- 2014
41. Response of black African patients with hepatitis C virus genotype 4 to treatment with peg-interferon and ribavirin
- Author
-
Nkuize, Marcel, Mulkay, Jean-Pierre, Adler, Michael, Lasser, Luc, Michielsen, Peter, De Galocsy, Chantal, Assene, Collins, Delwaide, Jean, Nkuize, Marcel, Mulkay, Jean-Pierre, Adler, Michael, Lasser, Luc, Michielsen, Peter, De Galocsy, Chantal, Assene, Collins, and Delwaide, Jean more...
- Abstract
Aim: To compare responses to therapy of Black African (BA) and non-Black African (non-BA) patients with hepatitis C virus genotype 4 (HCV-4) residing in Belgium. Methods: In this retrospective multicenter study, 473 patients with HCV-4 were selected from databases at 7 Belgian centers; 209 treatment-naïve patients (154 BA) had received treatment with peg-interferon (peg-IFN) plus ribavirin (RBV) and were included in the study. Results: There was a greater percentage of female patients in the BA group than in the non-BA group; BA patients were also older, had a greater body mass index, and more frequently had abnormal glucose metabolism. The route of contamination was more frequently unknown in BA than in non-BA patients and BA patients had more HCV-4 subtypes. There were no differences in other demographic factors between the groups. Sustained viral response (SVR) and complete early viral response rates were significantly lower and relapse rates significantly higher in BA than in non-BA patients. There were no differences between groups in rates of dose modification or in drug tolerance. Conclusion: In our cohort, treatment-naïve BA patients with HCV-4 who were treated with peg-IFN and ribavirin had a much lower SVR rate than treatment-naïve non-BA patients with HCV-4 who were treated with peg-IFN and ribavirin, and a higher relapse rate, possibly related to a weaker response to interferon-based therapy. Treatment may need to be adapted in this population., SCOPUS: ar.j, info:eu-repo/semantics/published more...
- Published
- 2013
42. High prevalence of advanced fibrosis in association with the metabolic syndrome in a Belgian prospective cohort of NAFLD patients with elevated ALT. results of the Belgian NAFLD registry
- Author
-
Francque, Sven, Verlinden, Willy, De Maeght, Stéphane, Deltenre, Pierre, Henrion, Jean, Adler, Michael, De Galocsy, Chantal, Orlent, Hans, Van Steenbergen, Werner, Bastens, Boris, Wain, Etienne, Langlet, Philippe, Lasser, Luc, Van Marck, Eric, Francque, Sven, Verlinden, Willy, De Maeght, Stéphane, Deltenre, Pierre, Henrion, Jean, Adler, Michael, De Galocsy, Chantal, Orlent, Hans, Van Steenbergen, Werner, Bastens, Boris, Wain, Etienne, Langlet, Philippe, Lasser, Luc, and Van Marck, Eric more...
- Abstract
Introduction: Non-alcoholic Fatty Liver Disease (NAFLD) is increasingly recognised as a source of liver related morbidity and mortality. Hard data on epidemiology and natural history are scarce. Aim: To study demographic and metabolic characteristics of the NAFLD patients seen by Belgian hepatologists. Methods: Belgian hepatologists filled in a questionnaire for every newly diagnosed NAFLD patient between January 1st and December 31st 2004. Liver biopsy was advised if ALT > 1.5 × ULN and if 3/5 of the criteria for the metabolic syndrome (MS) (ATPIII) were present, but was not mandatory. Biopsy was scored using the Brunt classification. Results: 230 patients were prospectively included in 9 centres; 54% were males; mean age was 49.4 ± 13.9 y; mean BMI was 30.6 ± 4.6 kg/m2. The MS was present in 53%. In 16% formerly undiagnosed diabetes was discovered. 51% had a liver biopsy: 25% met the criteria, 26% did not. Grading did not differ between patients with or without MS. Staging was significantly more severe in patients with MS (2.43 ± 1.25 vs. 1.73 ± 1.18, p < 0.001). A subgroup of patients with GGT > 5 × ULN were significantly older (55.9 vs. 47.64 y, p = 0.02), more frequently diabetic (53% vs. 23%, p = 0.01) and had more advanced fibrosis (3.42 vs. 1.08, p = 0.008). ALT levels were variable. Conclusions: The MS is highly prevalent in Belgian NAFLD patients and is associated with more severe disease. Mild to moderate fibrosis is frequent, and the proposed criteria for liver biopsy are not accurate in selecting these patients. Patients with elevated GGT constitute a subgroup with more advanced disease., SCOPUS: ar.j, info:eu-repo/semantics/published more...
- Published
- 2011
43. Upper gastrointestinal bleeding related to emphysematous cholecystitis due to Clostridium perfringens.
- Author
-
Gottignies, Philippe, Hossey, Didier, Lasser, Luc, Cherifi, Soraya, Devriendt, Jacques, De Bels, David, Gottignies, Philippe, Hossey, Didier, Lasser, Luc, Cherifi, Soraya, Devriendt, Jacques, and De Bels, David more...
- Abstract
We describe the case of a 46-year-old man admitted for upper gastrointestinal bleeding in the context of cirrhosis. A deep bleeding duodenal ulcer was treated by sclerotherapy. Abdominal pain and fever lead us to perform an abdominal computed tomography, which demonstrated emphysematous cholecystitis. An emergency cholecystectomy was performed and antimicrobial therapy initiated. The patient recovered uneventfully. Links between ulcers and emphysematous cholecystitis are discussed., Case Reports, Journal Article, SCOPUS: ar.j, info:eu-repo/semantics/published more...
- Published
- 2010
44. Clinical trial: A randomized trial of pegylated-interferon-α-2a plus ribavirin with or without amantadine in treatment-naïve or relapsing chronic hepatitis C patients
- Author
-
Langlet, Philippe, D'Heygere, François, Henrion, Jean, Adler, Michael, Delwaide, Jean, Van Vlierberghe, Hans, Mulkay, Jean-Pierre, Lasser, Luc, Brenard, Réginald, Horsmans, Y., Michielsen, Peter, Laureys, Annick, Nevens, Frederik, Langlet, Philippe, D'Heygere, François, Henrion, Jean, Adler, Michael, Delwaide, Jean, Van Vlierberghe, Hans, Mulkay, Jean-Pierre, Lasser, Luc, Brenard, Réginald, Horsmans, Y., Michielsen, Peter, Laureys, Annick, and Nevens, Frederik more...
- Abstract
Background The combination therapy of pegylated-interferon-α2a plus ribavirin is considered as the standard of care for patients with chronic hepatitis C. A sustained viral response is obtained in 40-50% of naïve patients with genotype 1 and in around 80% of naïve patients with genotype 2 or 3. Aim To assess whether amantadine, added to the conventional combination therapy, could improve the treatment efficacy. Methods In all, 630 patients (intent-to-treat population) with chronic hepatitis C were randomized into two groups: 316 patients (treatment group) received pegylated-interferon-α2a (180 μg once weekly) plus ribavirin (1000-1200 mg/daily) with amantadine (200 mg/daily); 314 patients (control group) received pegylated-interferon-α2a (180 μg once weekly) plus ribavirin (1000-1200 mg/daily) without amantadine. The duration of the treatment was 48 weeks for genotypes 1, 4, 5 and 6, and 24 weeks for genotypes 2 and 3. Results There was no statistically significant difference between treatments groups for any of the variables tested for. Subgroups of patients likely to take advantage of the addition of amantadine were not identified. Conclusions This large study definitely excludes the role of amantadine in addition of conventional combination therapy in the treatment of chronic hepatitis C patients. © 2009 Blackwell Publishing Ltd., SCOPUS: ar.j, FLWIN, info:eu-repo/semantics/published more...
- Published
- 2009
45. Etiology, management, and outcome of the Budd-Chiari syndrome.
- Author
-
UCL - (MGD) Service de gastro-entérologie, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, Darwish Murad, Sarwa, Plessier, Aurelie, Hernandez-Guerra, Manuel, Fabris, Federica, Eapen, Chundamannil E, Bahr, Matthias J, Trebicka, Jonel, Morard, Isabelle, Lasser, Luc, Heller, Joerg, Hadengue, Antoine, Langlet, Philippe, Miranda, Helena, Primignani, Massimo, Elias, Elwyn, Leebeek, Frank W, Rosendaal, Frits R, Garcia-Pagan, Juan-Carlos, Valla, Dominique C, Janssen, Harry L A, Martinet, Jean-Paul, UCL - (MGD) Service de gastro-entérologie, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, Darwish Murad, Sarwa, Plessier, Aurelie, Hernandez-Guerra, Manuel, Fabris, Federica, Eapen, Chundamannil E, Bahr, Matthias J, Trebicka, Jonel, Morard, Isabelle, Lasser, Luc, Heller, Joerg, Hadengue, Antoine, Langlet, Philippe, Miranda, Helena, Primignani, Massimo, Elias, Elwyn, Leebeek, Frank W, Rosendaal, Frits R, Garcia-Pagan, Juan-Carlos, Valla, Dominique C, Janssen, Harry L A, and Martinet, Jean-Paul more...
- Abstract
Fifth Framework Programme of the European Commission.
- Published
- 2009
46. Enteral nutrition with or without N-acetyslcysteine in the treatment of severe acute alcoholic hepatitis: a randomized, multicenter, controlled trial
- Author
-
EASL (2009: Copenhagen), Moreno, Christophe, Langlet, Philippe, Hittelet, Axel-Benoit, Evrard, Sylvie, Lasser, Luc, Colle, Isabelle, Lemmers, Arnaud, Devière, Jacques, Le Moine, Olivier, EASL (2009: Copenhagen), Moreno, Christophe, Langlet, Philippe, Hittelet, Axel-Benoit, Evrard, Sylvie, Lasser, Luc, Colle, Isabelle, Lemmers, Arnaud, Devière, Jacques, and Le Moine, Olivier more...
- Abstract
info:eu-repo/semantics/nonPublished
- Published
- 2009
47. Enteral nutrition with or without N-acetyslcysteine in the treatment of severe acute alcoholic hepatitis: a randomized, multicenter, controlled trial
- Author
-
Moreno, Christophe, Langlet, Philippe, Hittelet, Axel-Benoit, Evrard, Sylvie, Lasser, Luc, Colle, Isabelle, Lemmers, Arnaud, Devière, Jacques, Le Moine, Olivier, Moreno, Christophe, Langlet, Philippe, Hittelet, Axel-Benoit, Evrard, Sylvie, Lasser, Luc, Colle, Isabelle, Lemmers, Arnaud, Devière, Jacques, and Le Moine, Olivier more...
- Abstract
info:eu-repo/semantics/published
- Published
- 2009
48. Long-term (7-year-) treatment with lamivudine monotherapy in HBV-associated glomerulonephritis
- Author
-
Mesquita, Maria, Lasser, Luc, Langlet, Philippe, Mesquita, Maria, Lasser, Luc, and Langlet, Philippe
- Abstract
Glomerulonephritis (GN) is an uncommon but well-described complication of chronic hepatitis B virus (HBV) infection. HBV-related membranous nephropathy (MN) may lead to renal failure in 1/3 of the patients and spontaneous remission is rare. There is no standard therapy for HBV-associated MN. We report a case of a 28-year-old man with HBV-associated MN due to pre-core HBV mutant with complete remission under an on-going 7-year lamivudine monotherapy. ©2008 Dustri-Verlag Dr. K. Feistle., SCOPUS: ar.j, info:eu-repo/semantics/published more...
- Published
- 2008
49. What is the optimal duration of therapy in patients with hepatitis C genotype 2 or 3 infection? A review
- Author
-
Lasser, Luc, Langlet, Philippe, Lasser, Luc, and Langlet, Philippe
- Abstract
Pegylated interferon plus ribavirin is the standard treatment for chronic hepatitis C (HCV). Even if genotype 2 and 3 patients only request a treatment of 24 weeks, this treatment remains very costly and difficult to tolerate due to numerous side effects. Recently several studies focused on the possibility of further reducing treatment duration in chronic HCV genotype 2 and 3 patients without compromising sustained virological response (SVR). Based on the available data, patients presenting a negative PCR at week 4 named a rapid virological response (RVR) probably are the best candidates to benefit from shorter treatment duration. In contrast patients without RVR should at least be treated for 24 weeks and retrospective data suggest that a more intensive or prolonged therapy for 48 weeks could be necessary. However, at this moment it remains impossible to propose general recommendations for all patients with genotype 2 and 3. Therefore more randomized prospective trials are needed to clarify several issues that are discussed in this review article., SCOPUS: re.j, info:eu-repo/semantics/published more...
- Published
- 2008
50. L'hépatite C chez la femme en âge de procréer. Etat de la question
- Author
-
Langlet, Philippe, Lasser, Luc, Sidi, B., Langlet, Philippe, Lasser, Luc, and Sidi, B.
- Abstract
Chronic hepatitis C (VHC) is a worldwide public health issue. The mother-to-child transmission could be the main cause of hepatitis C infection in children. Despite the risk of histological injuries, chronic hepatitis C is not a contra-indication to pregnancy. In patients with VHC, there is no evidence that the outcome could be modified. In co-infected patients (VIH-VHC), a caesarean should be proposed taking into account the significant risk of mother-to-child transmission. Breast-feeding is not contra-indicated. Systematic screening of VHC, discussed in this article, could be proposed in woman planning a pregnancy., SCOPUS: re.j, info:eu-repo/semantics/published more...
- Published
- 2005
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.